Pure Global

A Feasibility Study of Supplemental Oxygen to Improve Pulmonary Hypertension in People With Intradialytic Hypoxemia - Trial NCT06327373

Access comprehensive clinical trial information for NCT06327373 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Duke University and is currently Not yet recruiting. The study focuses on Pulmonary Hypertension. Target enrollment is 10 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06327373
Phase 1/2
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06327373
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Feasibility Study of Supplemental Oxygen to Improve Pulmonary Hypertension in People With Intradialytic Hypoxemia

Study Focus

Pulmonary Hypertension

Oxygen

Interventional

drug

Sponsor & Location

Duke University

Durham,Durham,Durham,Durham,Durham,Durham,Durham,Durham,Henderson,Henderson,Roxboro, United States of America

Timeline & Enrollment

Phase 1/2

Jul 01, 2024

Jun 30, 2025

10 participants

Primary Outcome

Change daily hypoxemia burden

Summary

The purpose of this study is to assess the feasibility of supplemental oxygen delivery during
 hemodialysis in people with pulmonary hypertension and intradialytic hypoxemia.

ICD-10 Classifications

Primary pulmonary hypertension
Other secondary pulmonary hypertension
Pulmonary heart disease and diseases of pulmonary circulation
Pulmonary heart disease, unspecified
Pulmonary valve disorders

Data Source

ClinicalTrials.gov

NCT06327373

Non-Device Trial